Contact person:
Anette Gjörloff Wingren
  • EU RIA (Research and Innovation Action)
Responsible at MaU:
Anette Gjörloff Wingren
Collaborators :
  • Italy (coordinator)
  • Spain
  • Romania
  • Luxembourg
  • Germany
Time frame:
01 January 2020 - 31 December 2024

About the project

The main objective of REVERT is to develop an improved and innovative model of combinatorial therapy –based on personalised medicine – that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable metastatic colorectal cancer (mCRC).The REVERT project will address the specific challenge of understanding at system level the pathophysiology of mCRC cancer in patients responding well or poorly to therapies, to design optimal strategies for mCRC treatment on a case by case basis, with the evaluation of combinational therapies and the modulation of therapeutic interventions depending on the patient’s individual characteristics.